CICC released a research report stating that it maintains the “outperforming industry” rating of Federal Pharmaceuticals (03933.HK), the profit forecast remains unchanged, and the target price is HK$10.5. On April 23, the Joint Pharmaceutical Procurement Office of the State Organization issued the “Announcement of the Results of the National Centralized Drug Procurement (Special Insulin Special) Selection Results”, and all 6 products declared by Federal Pharmaceuticals won the bid in Group A.
中金:维持联邦制药(03933.HK)“跑赢行业”评级 目标价10.5港元
CICC: Maintaining Federal Pharmaceuticals (03933.HK)'s “outperforming the industry” rating target price of HK$10.5
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Statement
This page is machine-translated. Futubull tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.
Write a comment
0 0 0
LikeLoveLaughing CryRespectEmmSadAngry
Tap to Select a Mood
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
Use the share button in your browser
to share the page with your friends
Tap here to share
No comments yet. Write one.